Literature DB >> 22902723

Disease Progression in HIV-1-Infected Viremic Controllers.

Katherine C Groves1, David F Bibby, Duncan A Clark, Are Isaksen, Jane R Deayton, Jane Anderson, Chloe Orkin, Andrew J Stagg, Aine McKnight.   

Abstract

BACKGROUND: The mechanism of CD4 T-cell decline in HIV-1 infection is unclear, but the association with plasma viral RNA load suggests viral replication is involved. Indeed, viremic controller patients with low viral RNA loads typically maintain high CD4 T-cell counts. Within a local cohort of 86 viremic controllers, we identify a subgroup (18 "discord controllers") with low CD4 T-cell counts that present clinical uncertainty. The underlying mechanism accounting for CD4 T-cell decline in the face of low or undetectable plasma (RNA) viral load remains unresolved. The objective of this study was to investigate the viral and host immune system dynamics in discord controllers by measuring cellular HIV-1 DNA load, T-cell populations, and T-cell activation markers.
METHODS: We compared discord controllers (viral RNA load <2000 copies/mL, <450 CD4 T-cells/mm) with typical controllers (viral RNA load <2000 copies/mL, >450 CD4 T-cells/mm) and progressors (viral RNA load >10,000 copies/mL, <450 CD4 T-cells/mm). We quantified CD4/CD8 naive/central memory/effector memory subsets (CD45RA/RO ± CD62L), activation levels (CD38HLA-DR), and HIV-1 DNA load.
RESULTS: Discord controllers resembled progressors showing high viral DNA load, depletion of naive CD4 T-cells, and higher activation in all CD4 T-cell subsets, compared with typical controllers. They were similar to typical controllers with lower CD8 T-cell activation compared with progressors.
CONCLUSIONS: Our data are consistent with a relationship between CD4 T-cell activation and disease progression. HIV-1 DNA load may be a better marker of viral replication and disease progression than viral RNA load. Lower level CD8 T-cell activation correlates with low viral RNA load but not with disease progression or viral DNA load.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22902723      PMCID: PMC3736311          DOI: 10.1097/QAI.0b013e318269c414

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  47 in total

1.  Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.

Authors:  R P Bucy; R D Hockett; C A Derdeyn; M S Saag; K Squires; M Sillers; R T Mitsuyasu; J M Kilby
Journal:  J Clin Invest       Date:  1999-05-15       Impact factor: 14.808

2.  Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease.

Authors:  Shailesh K Choudhary; Nienke Vrisekoop; Christine A Jansen; Sigrid A Otto; Hanneke Schuitemaker; Frank Miedema; David Camerini
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

3.  Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection.

Authors:  Hanna Dreja; Eithne O'Sullivan; Corinna Pade; Kelli M Greene; Hongmei Gao; Keith Aubin; James Hand; Are Isaksen; Carl D'Souza; Werner Leber; David Montefiori; Michael S Seaman; Jane Anderson; Chloe Orkin; Aine McKnight
Journal:  J Gen Virol       Date:  2010-08-04       Impact factor: 3.891

4.  Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection.

Authors:  A M Dyrhol-Riise; P Voltersvik; B I Røsok; J Olofsson; B Asjö
Journal:  AIDS Res Hum Retroviruses       Date:  2000-02-10       Impact factor: 2.205

5.  Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.

Authors:  Z Liu; W G Cumberland; L E Hultin; H E Prince; R Detels; J V Giorgi
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-10-01

6.  Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.

Authors:  Richard Tilling; Sabine Kinloch; Li-Ean Goh; David Cooper; Luc Perrin; Fiona Lampe; John Zaunders; Bruno Hoen; Chris Tsoukas; Jan Andersson; George Janossy
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

7.  Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load.

Authors:  Steven G Deeks; Christina M R Kitchen; Lea Liu; Hua Guo; Ron Gascon; Amy B Narváez; Peter Hunt; Jeffrey N Martin; James O Kahn; Jay Levy; Michael S McGrath; Frederick M Hecht
Journal:  Blood       Date:  2004-04-29       Impact factor: 22.113

8.  CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B*5801-positive patient with an undetectable viral load.

Authors:  Adriana Andrade; Justin R Bailey; Jie Xu; Frances H Philp; Thomas C Quinn; Thomas M Williams; Stuart C Ray; David L Thomas; Joel N Blankson
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

9.  Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.

Authors:  Peter W Hunt; Jason Brenchley; Elizabeth Sinclair; Joseph M McCune; Michelle Roland; Kimberly Page-Shafer; Priscilla Hsue; Brinda Emu; Melissa Krone; Harry Lampiris; Daniel Douek; Jeffrey N Martin; Steven G Deeks
Journal:  J Infect Dis       Date:  2008-01-01       Impact factor: 5.226

10.  Altered representation of naive and memory CD8 T cell subsets in HIV-infected children.

Authors:  R L Rabin; M Roederer; Y Maldonado; A Petru; L A Herzenberg; L A Herzenberg
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

View more
  18 in total

1.  Natural control of HIV infection in young women in South Africa: HPTN 068.

Authors:  Mariya V Sivay; Jessica M Fogel; Jing Wang; Yinfeng Zhang; Estelle Piwowar-Manning; William Clarke; Autumn Breaud; Joel Blankson; Erica L Hamilton; Kathleen Kahn; Amanda Selin; F Xavier Gomez-Olive; Catherine MacPhail; James P Hughes; Audrey Pettifor; Susan H Eshleman
Journal:  HIV Clin Trials       Date:  2018-12-06

2.  Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers.

Authors:  Jonathan Z Li; Florencia P Segal; Ronald J Bosch; Christina M Lalama; Carla Roberts-Toler; Heloise Delagreverie; Rachel Getz; Pilar Garcia-Broncano; Jennifer Kinslow; Randall Tressler; Cornelius N Van Dam; Michael Keefer; Mary Carrington; Mathias Lichterfeld; Daniel Kuritzkes; Xu G Yu; Alan Landay; Paul E Sax
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

3.  Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics.

Authors:  Jonathan Z Li; Kelly B Arnold; Janet Lo; Anne-Sophie Dugast; Jill Plants; Heather J Ribaudo; Kevin Cesa; Andrea Heisey; Daniel R Kuritzkes; Douglas A Lauffenburger; Galit Alter; Alan Landay; Steven Grinspoon; Florencia Pereyra
Journal:  Open Forum Infect Dis       Date:  2015-01-13       Impact factor: 3.835

Review 4.  HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.

Authors:  Loredana Sarmati; Gabriella D'Ettorre; Saverio Giuseppe Parisi; Massimo Andreoni
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

5.  Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips" and Immune Activation in the ANRS CO21 CODEX Study.

Authors:  Nicolas Noel; Nathalie Lerolle; Camille Lécuroux; Cécile Goujard; Alain Venet; Asier Saez-Cirion; Veronique Avettand-Fenoël; Laurence Meyer; Faroudy Boufassa; Olivier Lambotte
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

6.  Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses.

Authors:  Nesrina Imami; Samantha J Westrop; Nathali Grageda; Anna A Herasimtschuk
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

Review 7.  The natural history of HIV infection.

Authors:  Caroline A Sabin; Jens D Lundgren
Journal:  Curr Opin HIV AIDS       Date:  2013-07       Impact factor: 4.283

8.  Limited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals.

Authors:  Nichole R Klatt; Steven E Bosinger; Melicent Peck; Laura E Richert-Spuhler; Anke Heigele; Jillian P Gile; Nirav Patel; Jessica Taaffe; Boris Julg; David Camerini; Carlo Torti; Jeffrey N Martin; Steven G Deeks; Elizabeth Sinclair; Frederick M Hecht; Michael M Lederman; Mirko Paiardini; Frank Kirchhoff; Jason M Brenchley; Peter W Hunt; Guido Silvestri
Journal:  PLoS Pathog       Date:  2014-08-28       Impact factor: 6.823

9.  Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection.

Authors:  Jintanat Ananworanich; Carlo P Sacdalan; Suteeraporn Pinyakorn; Nicolas Chomont; Mark de Souza; Tassanee Luekasemsuk; Alexandra Schuetz; Shelly J Krebs; Robin Dewar; Linda Jagodzinski; Sasiwimol Ubolyam; Rapee Trichavaroj; Sodsai Tovanabutra; Serena Spudich; Victor Valcour; Irini Sereti; Nelson Michael; Merlin Robb; Praphan Phanuphak; Jerome H Kim; Nittaya Phanuphak
Journal:  J Virus Erad       Date:  2016

10.  HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART.

Authors:  Jintanat Ananworanich; Nicolas Chomont; Leigh Ann Eller; Eugene Kroon; Sodsai Tovanabutra; Meera Bose; Martin Nau; James L K Fletcher; Somporn Tipsuk; Claire Vandergeeten; Robert J O'Connell; Suteeraporn Pinyakorn; Nelson Michael; Nittaya Phanuphak; Merlin L Robb
Journal:  EBioMedicine       Date:  2016-07-20       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.